BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30820806)

  • 1. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
    Zhang R; Chen J; Liu D; Wang Y
    Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
    Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
    Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
    Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
    World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.
    Wei L; Yang J; Wang M; Xu SN; Liang HM; Zhou Q
    Int J Mol Med; 2014 Nov; 34(5):1257-67. PubMed ID: 25174394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats.
    Klein S; Frohn F; Magdaleno F; Reker-Smit C; Schierwagen R; Schierwagen I; Uschner FE; van Dijk F; Fürst DO; Djudjaj S; Boor P; Poelstra K; Beljaars L; Trebicka J
    Sci Rep; 2019 Feb; 9(1):2256. PubMed ID: 30783172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urotension II antagonist SB-710411 arrests fibrosis in CCL4 cirrhotic rats.
    Liu DG; Wang J; Zhang ZT; Wang Y
    Mol Med Rep; 2009; 2(6):953-61. PubMed ID: 21475927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects.
    Klein S; Van Beuge MM; Granzow M; Beljaars L; Schierwagen R; Kilic S; Heidari I; Huss S; Sauerbruch T; Poelstra K; Trebicka J
    J Hepatol; 2012 Dec; 57(6):1220-7. PubMed ID: 22878469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Vilaseca M; García-Calderó H; Lafoz E; García-Irigoyen O; Avila MA; Reverter JC; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Hepatology; 2017 Jun; 65(6):2031-2044. PubMed ID: 28142199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of Shaoqiduogan on MMP-13, TIMP-1 expression in liver and hepatic stellate cells of hepatic fibrosis rats].
    Sun W; Gui S; Wu L; Wang H; Wei W
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1447-51. PubMed ID: 20822018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibitory effect of acupuncture on hepatic extracellular matrix production in carbon tetrachloride-induced liver fibrosis rats].
    Zhang F; Ma J; Lu Y; Ni GX; Ni CY; Zhang XJ; Wang AY; Zheng SZ
    Zhen Ci Yan Jiu; 2012 Feb; 37(1):8-14. PubMed ID: 22574562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
    Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
    Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
    Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
    Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
    Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats.
    Liu J; Peng L; Yang J; Wang M; Xu S; Liu J; Han P; He J; Tian D; Zhou Q
    Dig Dis Sci; 2015 Jul; 60(7):2019-29. PubMed ID: 25724163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
    Rodríguez S; Raurell I; Torres-Arauz M; García-Lezana T; Genescà J; Martell M
    Sci Rep; 2017 Jan; 7():40461. PubMed ID: 28084470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
    Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
    J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis.
    França MER; Rocha SWS; Oliveira WH; Santos LA; de Oliveira AGV; Barbosa KPS; Nunes AKS; Rodrigues GB; Lós DB; Peixoto CA
    Inflammopharmacology; 2018 Apr; 26(2):599-609. PubMed ID: 28409388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
    Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
    J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.